A Phase II Study of Amivantamab in People with Esophagogastric Cancer


Full Title

Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer


The purpose of this study is to assess the safety and effectiveness of amivantamab immunotherapy in people with metastatic esophagogastric cancer (cancer of the junction of the stomach and esophagus) that continues to grow despite treatment and contains too many copies of the EGFR or MET genes. Such “gene amplification” is common in cancer cells and can cause them to grow.

Amivantamab targets EGFR and MET proteins on cancer cells. It is given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have inoperable or metastatic esophagogastric cancer that continues to grow despite treatment. Their tumors must contain too many copies of the EGFR or MET genes.
  • At least 2 weeks must pass between the completion of prior treatment and receipt of amivantamab.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Steven Maron at 646-888-6780.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID